William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Herbalife in advanced talks to settle FTC probe, issues remain
-
The Pershing Square Sohn Cancer Research Alliance Awards Funding to Seven New York City-Based Cancer Research Scientists
-
Activism is 'alive and well' - Bill Ackman
-
Risk of being short Herbalife (HLF) at $59 is 'low' citing historic valuation multiples - Ackman
-
Herbalife (HLF) Short Position Remains the Same - Ackman
-
Valeant Pharma (VRX) may change its name at some point - Bill Ackman
-
Coca Cola (KO) product causes harm - Bill Ackman
-
Ackman defends Valeant, hints at more changes
-
Valeant Pharma (VRX) has no plans to sell 'crown jewel' assets - Bill Ackman
-
Bill Ackman regrets investing in Valeant Pharma (VRX)
-
Valeant Pharma (VRX) is not a 'sewer' - Ackman
-
Ackman compares Valeant Pharma (VRX) investment now to Warren Buffett's investment in Goldman Sachs (GS) in 2009
-
Valeant Pharma (VRX) Sharply Lower, But on Watch Ahead of Ackman CNBC Interview
-
Warren Buffett Comments on Valeant Pharma (VRX)
-
Buffett says Berkshire 'fine' with Trump or Clinton
-
Valeant annual report reveals new issues, company overhauls board
-
WPP Quarterly Trading Update
-
Valeant to name four new directors as soon as Friday: WSJ
-
Bill Ackman says that he expects Valeant Pharma (VRX) to file its 10k by Friday
-
Real estate activist Litt bets against IRET
-
Ackman, Valeant pledge reforms after spiking drug prices
-
House Democrats question if Valeant is withholding records
-
Herbalife (HLF) Gains Intra-Day Despite Ackman Presentation
-
Bill Ackman, Pearson, Schiller Among Valeant's (VRX) Senate Hearing Wtnesses
-
Valeant names Papa CEO after he resigns from Perrigo
-
Valeant in talks to hire Perrigo's Papa as CEO: source
-
U.S. activist investors finding fewer opportunities; compromise more common
-
Debt-laden Valeant faces tough choices in asset sales
-
Debt-laden Valeant faces tough choices in asset sales
-
Lone Pine's Cypress Fund down 8 percent in first quarter, hurt by Valeant
-
BettingonZero.com Created by Herbalife (HLF)
-
Does Ackman's Film on Herbalife (HLF) Have A Disclosure Problem?
-
Exclusive: Valeant calls in investment banks to weigh options - sources
-
Legg Mason's Miller Thinks Valeant (VRX) Stock Could Double, Has Been Buying Shares
-
'Betting on Zero' Doesn't Have Distributor Yet - Bloomberg (HLF)
-
S&P Downgrades Valeant Pharma (VRX) to 'B'; Notes Escalation in Near-Term Default Risk
-
Hedge funds' billion-dollar club loses members in 2015
-
Herbalife (HLF) on Watch Ahead of 'Betting on Zero' Premiere
-
Wall St. ends higher but indexes post weekly losses
-
Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb
-
Valeant gets extra month to file annual report
-
Pershing Square NAV/Share Up Modestly in April; YTD Return Ticked Higher Last Week
-
Valeant Pharma (VRX) Ramps to Session Highs
-
Ackman says Valeant may find new CEO in weeks, not months
-
Pershing Square's Ackman Says Valeant (VRX) was Passive Holding Until Recent, Board Focused on CEO Search
-
Ackman to face investor grilling after record quarterly loss
-
Ackman's fund falls 7 percent in March, hurt by Valeant
-
Regulator orders drugmaker Valeant management to cease trading
-
Historic 10-Year Anniversary of a Celebration of Heroes, Heart and Hope Gala in New York City Commemorating ‘A Decade of Difference’
-
Ackman's Amends Valeant Pharma (VRX) 13D to Add Director Consent for MCTO

